Microinjection of CART peptide 55-102 into the nucleus accumbens core inhibits the expression of conditioned hyperactivity in a cocaine-associated environment.
A distinct environment associated with psychomotor stimulants like cocaine and amphetamine can elicit conditioned locomotion in rats. This study examined the contribution of CART 55-102 peptide in the NAcc core to the expression of conditioned locomotion in a cocaine-associated environment. Rats in different groups were administered injections in five 2-day blocks: Paired, cocaine (15 mg/kg, IP) in locomotor activity boxes on day 1 and saline in their home cages on day 2; Unpaired, saline in the activity boxes on day 1 and cocaine in their home cages on day 2; or Control, saline in both environments. One week after the last conditioning block, all rats were tested for their conditioned locomotor response in the activity boxes for 1h following an IP saline injection, which was preceded by a bilateral microinjection into the NAcc core of saline or CART 55-102 (1.0 and 2.5 microg/side). As expected, Paired rats showed both increased locomotor activity and rearing compared to rats in either the Unpaired or Control groups. However, the expression of this conditioned hyper-locomotion was inhibited by microinjection into the NAcc core of CART 55-102. These results suggest that CART 55-102 peptide in the NAcc plays a role in the expression of conditioned locomotion in an environment associated with cocaine, and further extends the notion that CART 55-102 plays an important regulatory role in psychomotor stimulants actions in the NAcc.
Yoon
Hyung Shin
HS
Department of Physiology, Brain Korea 21 Project for Medical Science, Brain Research Institute, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, South Korea.
Kim
Wha Young
WY
Kim
Jeong-Hoon
JH
D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003042:Cocaine / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects*; D004347:Drug Interactions; D006948:Hyperkinesis / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000098882:Cocaine- and Amphetamine-Regulated Transcript Protein
D003042:Cocaine; D009419:Nerve Tissue Proteins; D010446:Peptide Fragments; C428723:cocaine- and amphetamine-regulated transcript protein (55-102); D000098882:Cocaine- and Amphetamine-Regulated Transcript Protein